US · LNSR
LENSAR, Inc.
- Sector
- Healthcare · Medical - Devices
- Headquarters
- Orlando, FL 32826
- Website
- lensar.com
Price · as of 2024-12-31
$5.61
Market cap 142.98M
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | $96.35 | +1,617.47% |
| Intrinsic Value(DCF) | $6.94 | +23.71% |
| Graham-Dodd Method(GD) | — | — |
| Graham Formula(GF) | — | — |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2010 | |||||
| 2011 | |||||
| 2012 | |||||
| 2013 | |||||
| 2014 | |||||
| 2015 | |||||
| 2016 | |||||
| 2017 | |||||
| 2018 | |||||
| 2019 | $0.00 | $0.00 | |||
| 2020 | $8.62 | $21.45 | $1.73 | $0.00 | $8.82 |
| 2021 | $6.25 | $55.66 | $2.92 | $0.00 | $0.00 |
| 2022 | $3.19 | $22.36 | $0.00 | $0.00 | $0.00 |
| 2023 | $4.09 | $49.73 | $3.35 | $0.00 | $0.00 |
| 2024 | $14.86 | $96.35 | $54.96 | $0.00 | $0.00 |
AI valuation
Our deep-learning model estimates LENSAR, Inc.'s (LNSR) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- $96.35
- Current price
- $5.61
- AI upside
- +1,617.47%
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
$6.94
+23.71% upside
Graham-Dodd
—
— upside
Graham Formula
—
— upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| LNSR | LENSAR, Inc. | $5.61 | 142.98M | +1,617% | +24% | — | — | -5.45 | 9.18 | 3.20 | -50.35 | -5.03 | 13.66 | 48.33% | -19.94% | -58.71% | -95.42% | -88.05% | -46.22% | 0.14 | — | 2.80 | 1.93 | 4.54 | 10840.00% | 2687.00% | -7543.00% | -1.42% | -0.15 | -20.07% | 0.00% | 0.00% | 0.00% | -14.19 | -62.24 | 2.83 | -0.11 |
| ANIK | Anika Therapeutics, Inc. | $14.36 | 207.09M | +157% | -53% | -61% | — | -18.87 | 1.43 | 1.82 | -93.81 | — | 1.54 | 56.56% | -9.80% | -9.64% | -7.32% | -9.43% | -5.54% | 0.17 | -6.34 | 4.72 | 3.71 | 18.15 | -8016.00% | -591.00% | -28713.00% | 2.12% | 0.51 | 3.72% | 0.00% | 0.00% | 6.37% | -15.57 | 39.44 | 1.53 | 3.99 |
| ARAY | Accuray Incorporated | $0.58 | 68.6M | +5,263% | +4% | -74% | — | -97.54 | 1.91 | 0.34 | 13.55 | — | 6.65 | 32.05% | 1.71% | -0.35% | -2.52% | 1.62% | -0.34% | 2.17 | 0.61 | 1.65 | 0.81 | 5.88 | -9031.00% | 268.00% | -6348.00% | -3.65% | 0.01 | -2.92% | 0.00% | 0.00% | 14.96% | 34.97 | -48.41 | 0.60 | 0.04 |
| AVR | Anteris Technologies Glob… | $6.51 | 239.49M | +229% | -58% | — | +1,116% | -1.66 | -1678.27 | 81.59 | -1.58 | -27.15 | -987.84 | 70.26% | 24.41% | -4925.51% | -300.71% | -5.60% | -181.73% | -24.54 | 6.40 | 0.73 | 0.59 | 0.11 | 610.00% | -2923.00% | 2251.00% | -49.85% | -3.64 | 932.39% | 0.00% | 0.00% | 0.00% | 312.17 | -1.87 | 76.21 | -18.68 |
| CRBP | Corbus Pharmaceuticals Ho… | $8.57 | 107.43M | — | — | — | — | -1.84 | 0.52 | — | 1.90 | — | 0.52 | 0.00% | — | — | -59.34% | 944.11% | -43.67% | 0.02 | -26.03 | 12.94 | 12.61 | 0.37 | -6431.00% | — | 1577.00% | -56.39% | -3.54 | 809.88% | 0.00% | 0.00% | 28.50% | 1.47 | 1.72 | — | -0.92 |
| CRDF | Cardiff Oncology, Inc. | $1.94 | 130.68M | +1,196% | -60% | — | +59% | -2.83 | 2.86 | 218.67 | -1.61 | — | 2.86 | -52.45% | -8256.32% | -7736.26% | -71.45% | 505.84% | -57.65% | 0.02 | — | 3.67 | 3.57 | 0.37 | -2737.00% | -1318.00% | 51.00% | -29.28% | -2.31 | 392.26% | 0.00% | 0.00% | 0.00% | -1.47 | -1.90 | 121.75 | -6.77 |
| MXCT | MaxCyte, Inc. | $0.81 | 86.54M | +3,073% | +164% | -99% | — | -8.96 | 1.78 | 9.53 | -4.99 | -165.84 | 1.78 | 81.62% | -132.54% | -106.29% | -18.73% | -67.18% | -16.17% | 0.09 | — | 10.88 | 10.09 | 0.21 | 541.00% | -644.00% | 1526.00% | -7.95% | -1.75 | -38.39% | 0.00% | 0.00% | 0.00% | -4.52 | -7.91 | 6.00 | 5.62 |
| OWLT | Owlet, Inc. | $11.55 | 184.81M | +401% | +393% | — | — | -5.81 | -3.44 | 0.93 | -6.80 | — | -3.29 | 50.36% | -25.90% | -16.06% | 49.33% | 68.11% | -26.78% | -0.56 | -12.40 | 1.27 | 0.89 | 0.88 | -8168.00% | 4452.00% | -4925.00% | -16.44% | -0.31 | 40.32% | 0.00% | 0.00% | 11.27% | -3.19 | -5.38 | 0.83 | -6.50 |
| PROF | Profound Medical Corp. | $7.61 | 229.84M | +279% | -61% | — | — | -6.11 | 2.81 | 16.71 | -4.69 | — | 2.82 | 65.89% | -309.57% | -260.45% | -60.70% | -267.75% | -48.72% | 0.08 | — | 10.52 | 9.44 | 1.95 | -2074.00% | 4123.00% | 373.00% | -13.80% | -3.57 | -199.52% | 0.00% | 0.00% | 18.51% | -3.82 | -5.12 | 11.81 | 5.24 |
| RPID | Rapid Micro Biosystems, I… | $4.33 | 191.92M | +463% | -78% | — | — | -2.22 | 1.38 | 3.71 | -1.28 | — | 1.38 | -0.39% | -177.96% | -167.16% | -48.50% | -155.83% | -38.81% | 0.08 | — | 4.61 | 3.32 | 0.23 | -1148.00% | 2457.00% | -300.00% | -43.71% | -2.51 | -142.09% | 0.00% | 0.00% | 0.00% | -1.19 | -1.31 | 2.12 | -4.66 |
| TLSI | TriSalus Life Sciences, I… | $5.06 | 167.17M | +547% | +1,763% | — | — | -4.73 | -5.49 | 4.83 | -4.35 | — | -5.49 | 86.06% | -122.88% | -112.92% | 113.47% | 150.57% | -123.72% | -0.91 | -11.70 | 2.02 | 1.33 | -0.42 | -4395.00% | 5899.00% | -1950.00% | -29.00% | -3.99 | 171.48% | 0.00% | 0.00% | 0.00% | -4.35 | -3.82 | 5.34 | -17.85 |
About LENSAR, Inc.
LENSAR, Inc., a commercial-stage medical device company, focuses on designing, developing, and marketing a femtosecond laser system for the treatment of cataracts and the management of pre-existing or surgically induced corneal astigmatism. Its LENSAR Laser System incorporates a range of proprietary technologies designed to assist the surgeon in obtaining visual outcomes, efficiency, and reproducibility by providing imaging, procedure planning, design, and precision. The company was incorporated in 2004 and is headquartered in Orlando, Florida.
- CEO
- Nicholas T. Curtis
- Employees
- 140
- Beta
- 0.65
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as ($6.94 ÷ $5.61) − 1 = +23.71% (DCF, example).